IGC Pharma Inc
Veridion Score
BETAMEDIUM CONF · 5/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is IGC moving today?
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
IGC overview
Related filings and maps
Congress activity in IGC
No receipt-qualified Congressional disclosure is present for IGC in the cached public ledger.
IGC contract awards, year to date.
Public federal awards linked to this ticker.
IGC lobbying filings, year to date.
Registered lobbying filings matched to IGC Pharma Inc.